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Abstract
Background: Chronic Obstructive Pulmonary Disease (COPD) is a treatable disease with a high prevalence, and
high morbidity associated with significant socioeconomic costs.
Objective: To carry out a systematic review of the literature to analyze the main cost studies associated with COPD,
in order to determine the main factors that influence the costs of the disease.
Methods: Searches were conducted in PubMed, SCOPUS and Web of Science databases for cost studies on COPD
published in English, between the years 2015 and 2020. The search terms were “COPD” OR “pulmonary disease,
chronic obstructive”, “cost*” OR “cost of illness”, “economic impact” AND “burden of disease”. The inclusion criteria
included the identification of reported cost of the disease, economic burden, medical care expenses or use
resources for COPD, the methodology used, data sources, and variables studied.
Results: 18 publications were analyzed: 17 included direct health costs, 6 included direct non-medical costs, 12
analyzed indirect costs and two reported intangible costs. Most of the studies reported data for developed and
European countries, with direct costs being the most studied. Trends were observed in multiple studies of direct
and healthcare costs for European countries measured by patient and year, where the higher costs were associated
with more severe COPD and a frequent history of exacerbations. The highest costs reported corresponded to
hospitalizations and the associated pharmacological treatment. The importance of the loss of productivity and
premature retirement within the profile of the COPD patient was also highlighted as the main generator of indirect
costs of the disease.
Conclusion: COPD generates substantial costs for the health system, mainly related to moderate to severe stages
and the exacerbations and complications entailed. It is important to strengthen health systems with monitoring,
evaluation and health education models that allow these patients to remain stable to avoid decompensation and
subsequent hospitalizations.
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Introduction
According to the Global Initiative for Chronic Obstruct-
ive Lung Disease (GOLD), COPD is defined as “a com-
mon, preventable, and treatable disease that is
characterized by persistent respiratory symptoms and
airflow limitation that is due to airway and/or alveolar
abnormalities usually caused by significant exposure to
noxious particles or gases” [1], tobacco being the main
cause detected [2].
The clinical manifestations of this heterogeneous dis-
ease are generally identified in people between the age of
40–50 years, although symptoms may appear earlier.
The main symptoms associated with the disease are dys-
pnea, chronic cough, and expectoration. These symp-
toms can often mislead the diagnosis, as they can be
confused with other chronic respiratory pathologies with
a similar course, such as asthma. The literature generally
identifies four phenotypes or clinical forms within the
disease that determine different treatments: non-acute,
with emphysema or chronic bronchitis, COPD-Asthma,
acute with emphysema and acute with chronic bron-
chitis [2].
The natural history of COPD includes episodes of ex-
acerbation, which become common in the moderate and
severe stages of the disease. These episodes increase
morbidity-mortality, health system resource utilization
(increased costs) and lead to loss of productivity and de-
terioration of the health-related quality of life (HRQoL)
of the patients who suffer from them [2, 3]. Exacerba-
tions are defined as an acute episode of clinical instabil-
ity characterized by a worsening of respiratory
symptoms” [2]. Patients with COPD experience an aver-
age of one to four exacerbations per year; however, the
intensity and duration varies from patient to patient,
making it difficult to quantitatively estimate their exact
consequences [2]. They are mainly related to respiratory
infections or environmental stressors, but sometimes
they can also be linked to the presence of other con-
comitant pathologies, which can produce a greater ag-
gravation of symptoms and, consequently, greater
difficulty for the patient’s recovery [4].
Epidemiologically, COPD is identified as the third
leading cause of death worldwide, besides representing
one of the main causes of increased morbidity, inducing
an economic and social burden that is currently on the
rise. The morbidity and mortality identified vary from
one country to another and from one population group
to another, which is why the existing prevalence data
widely differ [1].
Study justification
The main usefulness of cost-of-illness studies is based
on the identification and measurement of part of the fi-
nancial impact of the disease, at the health, social and
work levels, helping health system managers with limited
budgets and resources to cover a set of unlimited needs
and to make a cost-effective allocation between the in-
vestment options that exist and are presented to them in
their day-to-day activity.
In the case of highly prevalent chronic diseases, it is
essential to quantify the social and financial magnitude
of the disease in all spheres (direct and indirect costs,
health and non-medical costs, labor losses and intangible
costs). This will improve the ability to design, prioritize,
and apply preventive and health promotion measures,
investments in public health or social policies and proto-
cols and care guidelines in the most equitable and effi-
cient way possible. Furthermore, this will also allow
constant updating to prevent current practices from be-
coming obsolete, inefficient, and costly because they are
not adapted to the reality of the disease.
Various international studies have been carried out to
try to estimate the cost of COPD to society or to the
health care system, in different manners and applied to
different processes of the disease and with highly vari-
able study designs, thus obtaining heterogeneous results.
This variability in the methodology used by the different
authors makes it difficult to extrapolate results and con-
clusions, which can lead to a failure to make the most
appropriate and cost-effective decisions for managing a
disease with an ever-increasing prevalence in society. In
view of the wide variety of estimates, it is important to
develop a guide that provides a homogeneous estimate
and includes comparable data.
The principal aim of this systematic review was to
identify the main factors that lead to increased costs in
COPD patients.
Methods
A systematic review of the literature on COPD-
associated cost studies was conducted and served as the
basis for the design of the overall structure of this sys-
tematic review. The studies were identified and selected
by conducting a literature search using three electronic
databases: PubMed, SCOPUS, and Web of Science.
The terms included in the thesaurus of the National
Library of Medicine of the United States (Medical Sub-
ject Headings, MeSH) were used: “COPD or “pulmonary
disease, chronic obstructive”, “cost*” or “cost of illness”,
“economic impact” and “burden of disease” in the title
or abstract fields to retrieve potentially relevant publica-
tions in the last five years (January 1, 2015 to July 30,
2020). The search strategy was limited to publications
made in English and Spanish. The results were comple-
mented with a new review with free-text language with
keywords of the present monograph and filtering in the
last five years in the Google Scholar database after which
36 articles were selected (Table 1).
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The inclusion criteria consisted of systematic review
or original research, meeting the following conditions:
1. Reported cost of illness, economic burden, health
care expenditures, or use of resources for COPD.
2. Development of the methodology used for its
elaboration.
3. Identification of information on data sources and
study variables.
4. The study population included patients with the
disease under study: COPD.
5. Studies published in the last five years (January 1,
2015 - July 30, 2020).
6. Publications in English and Spanish.
Prior to conducting the literature search, a review
protocol was developed that included a timeline, the re-
search question, inclusion criteria for the articles to be
selected and a table for extracting data from the studies.
Figure 1 shows the procedure carried out, following the
guidelines proposed in the PRISMA Guide [5]. Thus, the
selection process was divided into four parts: identifica-
tion, screening, selection and inclusion. Identification
was carried out by means of the research question in the
different databases mentioned above. This phase yielded
359 results. After eliminating duplicate articles (n:233)
and exploring the literature, we proceeded to the screen-
ing phase, in which the 126 titles of all articles (359–
233) were examined and, following the aforementioned
inclusion criteria, those that were considered not rele-
vant were discarded (n:60). Those which were doubtful
proceeded to the third phase (n:66). One of the limita-
tions found and analyzed later lies in the high number of
duplicated articles, probably due to a failure related to
the level of hierarchy when establishing the combination
between search terms. But nevertheless, to facilitate the
management of the volume of articles, the selection
phase was divided into two sub-phases; a preliminary
phase in which the title and abstract of each of the
studies were reviewed for mention of the target popula-
tion of the study and the inclusion criteria were applied.
In this manner, the 66 articles mentioned above were
analyzed, after which 48 were discarded, subsequently,
in a second phase the studies were assessed as eligible
based on the full text. Finally, the remaining 18 articles
were included in the review and are presented in this
manuscript.
Results
This review highlights the significant economic burden
of COPD. Methodological heterogeneity was found in
the studies included in the review. The different authors
considered different variables to estimate direct health-
care costs, direct non-medical care costs, indirect costs
and intangible costs, and even used different quantifica-
tion methodologies and different economic conditions,
currencies, and billing years. In addition, the variability
among the different health systems in which the various
studies included in this review are framed must also be
considered. In summary, the studies used different ap-
proaches to estimate resource consumption. Although
each method is valid and appropriate and there is no
standard formula to be applied homogeneously in each
study, the resources allocated to the disease were identi-
fied differently, which can generate disparities in the cost
estimation.
This disparity leads to a wide variability of results for
the cost of COPD disease. Each perspective provides
useful and valid information on costs for a particular
group (different samples with different patient sociode-
mographic and disease-related characteristics), although
this makes comparison of results difficult.
First, the most relevant characteristics identified in the
eighteen selected articles are presented. The studies se-
lected in this systematic review included the following
designs: cohort study (n = 11), systematic review (n = 5)
and cross-sectional study (n = 2). These studies were
published between 2016 and 2020, thus presenting the
Table 1 Literature search strategy: PubMed, Scopus, Web of Science
Database Search terms Language Results
PubMed “COPD” AND “cost*” AND “economic impact” English 35
PubMed “COPD” AND “cost of illness” AND “burden of disease” English 29
PubMed “COPD” AND “burden of disease” AND “cost*” English 12
Scopus “COPD” AND “cost*” AND “economic impact” English 20
Scopus “COPD” AND “burden of disease” AND “cost*” English 19
Scopus “COPD” AND “cost of illness” English 134
Web of Science “COPD” AND “cost*” AND “economic impact” English 44
Web of Science “COPD” AND “burden of disease” AND “cost*” English 13
Web of Science “COPD” AND “cost of illness” English 17
Source. Own elaboration
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most updated data on the subject under study. The
monograph is based on a global setting; therefore the
analyzed articles were conducted mostly in Europe, but
also Asia and America. One of the most important as-
pects when carrying out a cost study and analyzing its
results is to identify the perspective presented by each
study. Thus, the present systematic review is made up of
studies with a societal perspective (9 articles), followed
by the perspective of the National Health System (4 arti-
cles), that of the patient (1 article) and that of the public
decision-maker (1 article). Finally, regarding the main
objective of the research studies analyzed, most studies
aim to evaluate the economic and social impact and bur-
den of COPD in the different health systems and soci-
eties where the studies are conducted, as well as to
identify the main factors that increase the cost of the
disease. These are the same objectives sought by the
present monograph. See Table 2.
As shown in Table 3 (methodological aspects of the
articles), first, the variables used to estimate costs were
identified. These were divided into several groups. Start-
ing with those variables related to the sociodemographic
characteristics of the patient and/or caregiver, mainly
elements such as age, sex, smoking, employment status
or socioeconomic status. Secondly, it is also important
to highlight the presence, in most of the included stud-
ies, of variables that respond to patient characteristics
related to the disease, mainly: GOLD stage, COPD sever-
ity, years of follow-up of the disease, respiratory symp-
toms or the CAT scale (COPD impact and quality of life
test). This leads to the variables related to direct health
care costs, mainly consisting of the costs of patients hos-
pitalized for COPD and/or other causes, outpatient
costs, drug costs or costs of visits to the emergency de-
partment. In relation to direct non-health costs, these
mainly include the variables of the cost of home oxygen,
medical transport, and informal care. Furthermore, there
are variables that study indirect costs, in this case mainly
related to loss of productivity and absenteeism, early re-
tirement or premature mortality. Finally, we find the var-
iables related to the study of intangible costs, where
HRQOL and DALYs are identified.
This table shows the main limitations identified by the
authors of the articles included in the monograph, with
many of them agreeing on the difficulties identified. In
summary, we can highlight the variability between
Fig. 1 Flow diagram of literature search
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countries (both in terms of patients and health services),
cultural differences and differences in health practices,
recall and selection bias (which can lead to an underesti-
mation or overestimation of costs), difficulties in reach-
ing the sample size, heterogeneity in designs between
studies, differences in the level of COPD severity of the
patients selected, and the non-inclusion of the costs of
exacerbations in some of the articles. See Table 3.
As shown in Table 4, the direct healthcare costs (17
articles), are the most studied and are present or referred
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*NHS: National Health System
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Table 3 Methodological aspects of the articles: variables collected to estimate direct healthcare costs, direct non-medical costs,
indirect costs and intangible costs, and limitations
Article Variables collected Limitations
Foo J et al. [6] Sociodemographic characteristics of the patient: sex, age, years
working, Patient characteristics related to the disease: COPD
severity, mMrc, CAT and comorbidities. Direct healthcare costs:
moderate and severe exacerbations, contact with health professionals,
COPD medications, and flu vaccination in the past 12 months.
Indirect costs: lost productivity and associated annual gain based on
the above loss.
The different local unit costs of health services in each
country had a limited impact on the variability between
different countries. There is also wide variability among
COPD patients surveyed in various countries. Direct costs
are likely to depend on health systems and patient access
to health care. Developed countries where access to care
is often free tend to have higher costs. Other factors
influencing variations in the data could be related to
cultural differences and health practices.
Wacker M. E
et al. [7]
Sociodemographic characteristics of the patient: age, sex, smoking
and educational level. Patient characteristics related to the
disease: FEV1, BMI, concomitant pathologies (MD, cerebrovascular
accident (CVA), acute myocardial infarction (AMI), cancer and arthritis).
Direct healthcare costs: visits to the doctor (last 3 months) and 13
specialties and prescribed drugs. Indirect costs: work absenteeism
(last 12 months) and early retirement.
Regional restriction of the control group, possible selection
bias that could have resulted in underestimation or
overestimation of excess COPD costs, limiting the potential
for external validation. Recall bias in interviews to record
direct healthcare costs. Additional health services such as
nursing or premature death costs were not considered.
Cohort had to be free of moderate-severe exacerbations in
the last 4 weeks before participation.
Chen W et al.
[8]
Sociodemographic characteristics of the patient: age and sex.
Patient characteristics related to the disease: comorbidities. Direct
healthcare costs: inpatient costs, outpatient costs and prescribed
drugs.
The impact of COPD severity on comorbidity costs was not
assessed because information on pulmonary function
measures in health data was missing. Lack of information
from missing diagnosis registries. The study did not adjust
cost estimates using survival for each year of follow-up.
Tachkov K
et al. [9]
Sociodemographic characteristics: of the patient age and sex.
Patient characteristics related to the disease: severity of COPD.
Indirect costs: absenteeism (loss of productivity due to sick leave)
and presenteeism (loss of productivity due to reduced work capacity),
early retirement or permanent reduction in work capacity. Intangible
costs: DALY.
Short follow-up period (1 year). Use of GDP per capita. In
the calculation of DALY, YLL was assumed to be 0, because
no patients died during the study period. This linked DALY
directly to years of disability.
Wacker M. E
et al. [10]
Sociodemographic characteristics of the patient: sex, age, smoking
and educational level. Patient characteristics related to the
disease: GOLD stage, spirometry variables, BMI, comorbidities, and
symptoms (cough, expectoration, dyspnea, or no symptoms). Direct
healthcare costs: outpatient costs, hospitalizations, and medication
costs. Indirect costs: absence from work and early retirement.
The central data are based on self-reported information by
study participants (recall bias). Consequently, the economic
burden of COPD could be underestimated. History of exac-
erbations was not included as a possible cost factor. The
design does not allow investigating whether COPD-related
costs are increased by comorbid conditions.
Quang Vo T
et al. [11]
Sociodemographic characteristics of the patient: age, sex and
health insurance status. Direct healthcare costs: drugs and medical
examinations, laboratory and functional tests and hospitalization costs.
The retrospective design may have led to loss of data. The
data used were from a public hospital database; therefore,
the results are primarily applicable to public care settings.
The accuracy of diagnosis and management was sensitive
to the diagnostic criteria used by the reporting physicians.
Lakiang T
et al. [12]
Sociodemographic characteristics of the patient: age, marital
status, employment status, number of family members, health
insurance, monthly income, and educational level. Direct healthcare
costs: visits by healthcare professionals, prescribed drugs, and
hospitalizations. Direct non-medical costs: medical transportation
and meals. Indirect costs: absolute absenteeism, relative absenteeism,
work hours lost, absolute absenteeism and relative absenteeism.
The total sample size was not achieved, as many of the
patients who were identified as subjects were retired or
had not been working for more than one month, so they
were excluded from the study. The sample size was
compromised regarding the productivity and absenteeism




Sociodemographic characteristics of the patient: age and sex.
Patient characteristics related to the disease: comorbidities and
pharmacological treatment. Direct healthcare costs: COPD drugs, all
drugs, nights hospitalized for COPD, nights hospitalized for other
causes, hospital visits for COPD, hospital visits for other causes, doctor
visits, visits by other health professionals. Indirect costs: loss of
income in COPD patients.
The retrospective design of the study means that it may
be subject to bias and confounding. The results for
absolute cost have limited generalizability outside Sweden,
as cost structures, prices, and supply differ between
countries. Some sources of costs (personal care and others
attributable to family caregivers) may have been
overlooked The reference population was identified from
patients without COPD who were required to attend the
study’s Primary Care centers rather than healthy individuals
from the general population.
Merino M
et al. [14]
Sociodemographic characteristics of the patient: sex, age,
smoking, educational level and employment category. Patient
characteristics related to the disease: spirometry parameters,
disease severity, exacerbations in the last 12 months, number and
description of comorbidities and BMI. Sociodemographic
characteristics of the caregiver: gender, age and relationship to the
patient. Direct healthcare costs: medical tests (blood tests, pre-post
The severity level of COPD was missing in most (58.3%) of
the participants’ medical records. Resource use
corresponds to those associated with COPD in the last 12
months, but it is possible that a proportion is not strictly
associated with COPD but with its related comorbidities.
Recall bias in relation to work hours lost in the last 12
months of working patients (7.9%).
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Table 3 Methodological aspects of the articles: variables collected to estimate direct healthcare costs, direct non-medical costs,
indirect costs and intangible costs, and limitations (Continued)
Article Variables collected Limitations
spirometry, alpha-I anti-trypsin, X-rays, CAT scan and blood gas), pneu-
mologist visits, Emergency Department visits, hospital admissions and
prescribed drugs. Direct non-medical costs: permanent stay in a
home or residential center, attendance at a day care center, profes-
sional home care, informal care, use of medical transportation, home
oxygen, and number of informal caregivers. Indirect costs: labor
productivity losses.
Patel JG et al.
[15]
Sociodemographic characteristics related to the patient: age, sex,
geographic region, type of plan, type of eligibility (leave + short-term
disability, leave only or short-term disability only) and type of industry.
Patient characteristics related to the disease: comorbidities. Direct
healthcare costs: Assessments, hospitalizations, doctor’s visits, visits to
other professionals and prescribed drugs. Indirect costs: absenteeism
and short-term disability.
The small sample size limits the interpretation of the
impact of exacerbation frequency on absenteeism in the
current study. The models were adjusted for comorbidities
included in the CCI, rather than a complete list of possible
comorbidities, which means that some conditions may not
have been considered. The indirect cost estimate only
considers short-term disability and not absenteeism, pres-
enteeism, or long-term disability. This may underestimate
the costs to an employer. In addition, the short-term dis-
ability data were extracted from the MarketScan database
whose purpose and consistency have not been confirmed.
The exacerbator status assessment used medical claims to
define exacerbator groups in the same period as the out-
comes. This potentially confounded the impact of exacer-
bations on direct costs.
Stafyla E et al.
[16]
Sociodemographic characteristics of the patient: age, sex,
occupational exposure, employment status and smoking. Patient
characteristics related to the disease: BMI, years with COPD,
spirometry parameters, respiratory symptoms, comorbidities, GOLD
stage and GOLD group. Direct healthcare costs: pharmacological
treatment, medical visits, respiratory function tests, vaccinations, and
laboratory tests. Direct non-medical costs: transport and home
oxygen.
This study was designed to estimate the direct cost of
COPD during the maintenance phase and not to assess
the cost of exacerbations, which contributes a significant
proportion of total cost in many studies. Due to the
absence of related data, indirect costs could not be
calculated. A large proportion of patients visited NHS units
free of charge, so the cost of medical visits was
underestimated. A final limitation could be the small
population size.
Zhu B et al.
[17]
The number of studies included in the review was 47 with an average
quality assessment score of 7.70 out of 10. Direct healthcare costs,
direct non-medical care costs, indirect costs and intangible costs
were evaluated: 13 studies evaluated quality of life.
N/A*
Changhwan
Kim M. D et al.
[18]
Direct healthcare costs: Outpatient and inpatient care, emergency
room visits and prescribed drugs. (Formal + informal) Direct non-
medical costs: transportation, home care and nursing costs. Indirect
costs: premature mortality and productivity losses.
Sample size. Patient survey data were used to estimate
direct nonmedical and indirect costs for the first time in
Korea. The survey data were entirely patient-reported (re-
call bias). An attempt was made to recruit patients from
primary clinics to tertiary hospitals. Most of the sample
were tertiary hospital patients, so direct medical costs per
patient were higher in tertiary care hospitals than in pri-




The number of studies included in the review was 40. Direct




Sociodemographic characteristics of the patient: age and sex.
Patient characteristics related to the disease: BMI, spirometry
parameters, comorbidities, years of disease follow-up and deaths due
to COPD or other causes. Direct healthcare costs: medical visits (out-
patient + emergency), hospitalization days, medical procedures and
surgeries, and laboratory.
It is likely that costs associated with medical care were
underestimated, since all hospital days were valued equally
in the analyses, however, severe exacerbations of COPD
are treated with costly treatment that could not be
assessed in this study. Indirect costs were not considered.
Data were taken from specialty care hospital records,
patients with severe COPD were likely referred or their
exacerbations treated in specialty care whereas patients
with non-severe COPD would have had a reason to go to
specialty care (diagnostic purposes), therefore patients with
non-severe COPD in this study likely had higher associated
health costs than non-severe patients treated at the Pri-
mary Care level. Risk of data collection from unconscious
patients that may affect population size and other
outcomes.
Woo L et al.
[21]
The number of studies included in the review was 10. Direct and
indirect costs were evaluated.
N/A
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to in 17 out of 18 studies. These are followed by studies
analyzing indirect costs (13 articles), direct non-health
costs (8 articles) and finally, intangible costs (2 articles).
The main structure presented by most of the studies
starts with an analysis of direct health costs, followed by
direct costs unrelated to health, and finally by indirect
costs. As traditionally occurs in cost-of-illness studies,
the least studied costs were the intangible costs, since
only 2 of the 18 studies included these in their research.
This is possibly due to the lack of information and re-
cords and the difficulty of their evaluation, quantifica-
tion, and subsequent analysis, since it is very difficult to
create a monetary value for aspects such as health-
related quality of life (HRQoL) or disability.
In short, the heterogeneity of the studies makes it diffi-
cult to compare results. In this regard, the cost varies
greatly depending on the countries studied, whether they
have public or private health systems and whether they
are conducted in developed or developing countries. In
conclusion, a great variability was found in the costs re-
ported in the studies, where the total cost per COPD pa-
tient varies strikingly between geographically distant
areas.
Starting with direct health care costs, the data are ana-
lyzed and presented for the different geographical areas
studied. Thus, in Europe (the geographic area where
most of the studies in this monograph are set), this cost
ranges from high-cost areas such as Norway at €10,701
(€/2019) per patient per year and Belgium at €1963
(€/2019) per patient per year. The average cost estab-
lished among eight European countries (Norway,
Denmark, Germany, Italy, Sweden, Greece, Belgium, and
Serbia) for total direct costs per patient per year is
€6182 (€/2019) [23]. Secondly, in the case of Asia, re-
garding the direct healthcare cost, no major significant
differences were found among the developed Asian
countries (Japan, South Korea, Singapore, Taiwan, and
China). The average is estimated at approximately $9172
(USD/2017) [21]. Finally, in the USA, the figures remain
between $9981 (USD - N/A) and $6246 (USD/2010)
[15].
Considering the indirect costs (the second most stud-
ied), starting again with Europe, Rehman et al. [23], in
their recent published systematic review of European
studies established that the loss of productivity was high-
est in Germany with €5735 and the lowest in Greece
with €998. This productivity loss was estimated at €4824
in Bulgaria, €2033 in Denmark and €1298 in Sweden. In
the case of Asian countries, the total annual social costs
ranged from $4398 to $23,049 per capita in Japan and
from $453 to $12,167 in South Korea, $2700 in
Singapore, $4000 in Taiwan, $3942 in China, and $1105
in Thailand [21]. Finally, Patel et al. [15] (2018) pub-
lished in the USA that the loss of productivity was 5
more days/year of absence from work in patients with
COPD and an increase in short-term disability of $641
compared to patients without the disease.
The following are direct non-health care costs, these
types of costs are present in eight of the 18 articles ana-
lyzed in this review, many of which have already been
included in the section on direct healthcare costs. There
are some exceptions that report total direct costs, mak-
ing no distinction between health and non-medical
costs.
Finally, only two authors included intangible costs in
their articles. In summary they established that patients
with mild COPD spend 0.62 years of their life in disabil-
ity, for those with moderate COPD this can represent as
much as 6 years, and in the case of severe stages of the
disease, this figure amounts to 9 years y reporting that
Table 3 Methodological aspects of the articles: variables collected to estimate direct healthcare costs, direct non-medical costs,
indirect costs and intangible costs, and limitations (Continued)
Article Variables collected Limitations
Iheanacho I
et al. [22]
The number of studies included in the review was 73. Direct
healthcare costs and direct non-medical costs (22 articles) and




The number of studies included in the review was 19. Direct and
indirect costs were evaluated.
N/A
Source. Own elaboration
*N/A ➔ Not applicable
*COPD: Chronic obstructive pulmonary disease
*mMrc: Modified scale of Medical Research Council
*CAT: COPD Assessment Test
*FEV1: Peak expiratory volume in the first second
*BMI: Body mass index
*MD: Mellitus diabetes
*CVA: Cerebrovascular accident
*AMI: Acute myocardial infarction
*DALY: Disability adjusted life years
*GDP: Gross domestic product
*GOLD: Global initiative of chronic obstructive lung disease
*NHS: National health service
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Table 4 Economic aspects of the articles: currency/year and estimated cost (direct healthcare costs, direct non-medical care costs,

















Foo J et al.
[6]
2016 YES NO YES NO Dollars –
N/A*
Direct healthcare costs: It ranged from US$ 504 (South
Korea) to US$ 9981. Indirect costs: Ranged from $979
(RuYESa) to $20,844 (U.S.).
Wacker M. E
et al. [7]
2016 YES NO YES NO Euros/
2012
Direct healthcare costs: 2595 for COPD Grade 1, 3475
for Grade 2, 5955 for Grade 3 and 8924 for Grade 4.
Indirect costs: 8.621 Grade 1, 9871 Grade 2, 16,550
Grade 3 and 27,658 Grade 4.
Chen W
et al. [8]
2017 YES NO NO NO Canadian
dollars
/2015




2017 NO NO YES YES Euros –
N/A
Indirect costs: average annual per patient €521.45. The
average due to early retirement €25,000 (€6250 per
patient) and for presenteeism €3750.64 per year.
Intangible costs: a patient with mild COPD spends 0.62
years of his or her life in disability, moderate 6.00 and




2017 YES NO YES NO Euros/
2012
Direct healthcare costs: 7263 per patient (48.8%
hospitalization, 34.1% prescribed medication, 11.7%
medical and outpatient consultations and 7.4%
rehabilitation and physiotherapy). Indirect costs: €23.298.
Quang Vo T
et al. [11]
2018 YES NO NO NO Dollars
/2017
Direct healthcare costs: ranged from $22.4 to $32.7 per




2018 YES YES YES NO Indian
Rupee (Rs)
– N/A
Direct healthcare costs: 29.885 ± 11.995,33 Rs. Direct
non-medical costs: 7.441,25 ± 2.228,90 Rs. Indirect
costs: The mean absenteeism observed in the last 28
days was 193.50 ± 33.62 h. The mean absolute
absenteeism was 72.05 ± 7.55 h.
Lisspers K
et al. [13]
2018 YES NO YES NO Euros/
2013




2018 YES YES YES NO Euros/
2015
Average annual cost per patient of €3077. Direct
healthcare costs: € 1.645 (43,8%). Direct non-medical
costs: € 1.440 (38,3%). Indirect costs: € 672 (17,9%).
Patel JG
et al. [15]
2018 YES NO YES NO USD/2010 Direct healthcare costs: $6246 patient/year. Indirect
costs: Productivity loss was 5 more days/year of absence
from work in COPD patients and an increase for short-
term disability of $641. Direct costs for frequent and infre-




2018 YES YES NO NO Euros –
N/A
Total direct cost: The mean annual direct cost per
stable disease was estimated at €1034.55 per patient, of
which €222.94 corresponded to out-of-pocket payments.
The annual cost ranged from €408.23 to €2041.89 accord-
ing to GOLD stages (I-IV) and from €550.01 to €1480 ac-
cording to GOLD groups (A-D).
Zhu B et al.
[17]
2018 YES YES YES YES USD – N/
A
Total direct cost: 499–1.930 USD per capita per year.
Direct medical costs: 72–3.565 USD per capita per year.
Indirect costs: 20–783 USD per capita per year
Intangible costs: quality of life status is worse among
patients with COPD than in patients without COPD and




2019 YES YES YES NO USD – N/
A
Total costs: 1245 million USD. Direct healthcare costs:
206.909 thousand USD (formal) AND 44.239 thousand
USD (informal) Direct non-medical costs: USD 4262
thousand (transportation) and USD 486.3 million (nursing)
Indirect costs: 407,771 thousand (lost productivity) and
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the quality of life was worse among patients with COPD
than in patients without COPD and also that they had a
higher risk of depression during the course of the dis-
ease than patients who did not suffer from the disease.
See Table 4.
Discussion and conclusions
COPD is one of the main chronic diseases identified in
developed countries. The latest epidemiological data in-
dicate a high growth rate, which is projected even more
intensely into the future, mainly related to population
aging and smoking, which is present in western societies
with worrying figures. Its identified morbimortality is
one of the factors that disrupts the economic stability of
health institutions, which is one of the basic pillars of a
nation, and consequently increases the costs attributable
to society at large [1, 2].
Regarding the characteristics of the selected articles
(Table 2) and their methodological aspects (Table 3), it
is important to note that the variability of costs in the
reported results are largely a consequence of methodo-
logical divergences and research objectives that impact
the type of costs in the way existing resources are identi-
fied, measured, valued and consumed by COPD patients
in the various study settings. This variability may also be
due in part to real differences between countries, such as
epidemiological differences, differences in the sociode-
mographic characteristics of the patients included in the
analyses, the main characteristics of the health systems
in each area and even differences in the prevention and
treatment of COPD and its complications, as well as the
way professionals work and cultural differences.
In the case of the economic characteristics of the se-
lected articles (Table 4), one of the limitations found
was that health cost studies report their results in
Table 4 Economic aspects of the articles: currency/year and estimated cost (direct healthcare costs, direct non-medical care costs,

















USD 96,153 thousand (premature deaths).
Rehman A
et al. [19]
2019 YES NO NO NO USD –
2019
Direct healthcare costs: In the USA, the annual direct
medical cost was $10,367 and the hospitalization cost
was $6852. In Asia, the annual direct medical cost per
patient in Iran, Korea and Singapore was $1544, $3077
and $2335, respectively. That of hospitalization in Iran,
Korea, Singapore, India, China, and Turkey was $865,
$1371, $1868, $296, $1477 and $1031, respectively. In
Europe, the annual direct medical cost per patient was
$11,787 (Norway), $10,552 (Denmark), $8644 (Germany),
$8203 (Italy), $7760 (Sweden), $3190 (Greece), $1889
(Spain), $2162 (Belgium) and $2254 (Serbia).
Viinanen A
et al. [20]
2019 YES NO NO NO Euros –
N/A
Direct healthcare costs: 3300–3900 per patient per year.
Severe disease €564 vs non-severe €319 (patient/year) Se-
vere COPD patients with eosinophils €5215 vs non-
eosinophilic COPD €4456 and €2538 in patients with un-
known eosinophilic status (patient/year).
Woo L et al.
[21]
2019 YES YES YES NO USD/2017 Total costs: Total annual social costs ranged from $4398
to $23,049 per capita in Japan and from $453 to $12,167
in South Korea. Remaining countries: $2700 (Singapore),
$4000 (Taiwan), $3942 (China) and $1105 (Thailand).
Iheanacho I
et al. [22]
2020 YES YES YES NO N/A Direct costs: Most studies reported data from Europe or
North America. Trends were observed in multiple studies
due to higher direct costs being associated with
increasingly severe COPD and/or a history of more




2020 YES YES YES NO Euros/
2019
Direct costs: per patient per year was €10,701 (Norway),
€9580 (Denmark), €7847 (Germany), €7448 (Italy), €7045
(Sweden), €2896 (Greece), €1963 (Belgium) and €2047
(Serbia). Indirect costs: Loss of productivity was highest
in Germany €5735 and lowest in Greece €998. It was
estimated at €4824 (Bulgaria), €2033 (Denmark) and
€1298 (Sweden).
Source. Own elaboration
*N/A ➔ Not applicable
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different currencies (apart from some intangible cost
studies). As this systematic review comprises worldwide
studies, each study was conducted in a different geo-
graphical setting, consequently presenting its results in
different currencies (euros, Indian rupee, Canadian dol-
lar, or US dollar), as well as computing this value in dif-
ferent years, from 2010 for the oldest study to 2019 for
the most recent. This, in turn makes it difficult to equate
and compare results unanimously, which generates dis-
crepancies and heterogeneity when presenting and
reflecting on the results found. Secondly, the studies
identified in this review clearly show that there are not
many studies that simultaneously estimate direct health-
care costs, direct non-medical care costs and indirect
costs. Only three authors carried out such a study [12,
14, 18]. The scarce presence of non-medical costs, which
refer to items such as the costs derived from personal
care (formal and informal) and the transport or subsist-
ence costs required by the disease, is noteworthy. Less
than half of the studies identified incorporated this item
in some way, and if they did, in most cases they comple-
mented healthcare costs. However, none of them in-
cluded the family cost related to the care of persons as a
consequence of the disease. Also, it is important to men-
tion that some studies are based on the perspective of
COPD cost calculation and others show the total attrib-
utable costs in COPD patients (in this case older pa-
tients) since the costs generated by the comorbidities
and peculiarities of each patient in the study sample are
also included.
In view of the objectives of this monograph, it is im-
portant to mention that the 18 cost studies identified in
this systematic review indicate that COPD significantly
increases overall economic costs, thus generating signifi-
cantly higher excess costs for people with COPD, com-
pared to people without the disease. Regarding the
factors that increase costs in COPD patients, after read-
ing and analyzing the 18 articles included in the review,
the main link that leads to the greatest increase in costs
in this pathology is AECOPD (acute exacerbation of
COPD), the main complication, which occurs more fre-
quently and is greater with more severe COPD and cases
that are worse controlled. Thus, the patients who gener-
ate the most costs within the disease are those who are
in a moderate-severe stage of the disease and who, in
addition, have the worst control of their pathology. Poor
control of respiratory disease in general, and specifically
in the COPD patient, is based on poor adherence to
treatment and a lack of skill or technique in carrying out
the prescribed pharmacological treatment. This, together
with the presence of other risk factors such as smoking
or obesity and factors external to the patient, such as en-
vironmental conditions or aging, lead to an increase in
the number of exacerbations, which in most cases can
lead to visits to the emergency department or even hos-
pitalizations that generate high costs, which, in addition
to the patient’s own comorbidities, can be lengthy. These
comorbidities are the second most present factor which
the studies refer to the most regarding the increase in
costs, since patients with a greater number of chronic
diseases generate increased costs, due to a greater con-
sumption of drugs, greater hospital and outpatient visits,
the performance of greater functional and laboratory
tests, and, directly and indirectly affecting parameters
that make up work losses, increased disability, loss of
HRQOL or the need for the presence of an informal
caregiver to support the patient’s basic care.
Finally, a breakdown by type of cost shows that all the
authors reached the consensus that the main compo-
nents of direct healthcare costs are hospitalizations (pro-
duced in most cases by AECOPD) and medication to
treat these complications, whereas in general the other
components (medical visits, emergency visits, diagnostic
tests) are less relevant. Likewise, regarding indirect costs,
the studies identified highlight the importance that work
losses can have as a consequence of the disease. These
are reported by more than half of the authors included
in the literature review. This aspect entails not only a
loss for the employer or society as a whole, but also a
direct impact on the economic stability of the individuals
facing the disease and, consequently, also on their fam-
ilies or persons on whom their economic income
depends.
In conclusion, given the importance of COPD, both
for the health system and for society, it would be advis-
able to reassess the allocation of resources for the dis-
ease by taking into account the study of costs.
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